×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SYRS – syros pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SYRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
12:36 pm
syrs
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]
Medium
Report
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal [Yahoo! Finance]
11/4
11:14 pm
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/4
11:00 am
syrs
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
Low
Report
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
11/3
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
Medium
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
11/2
11:00 am
syrs
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Medium
Report
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
11/2
10:55 am
syrs
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) [Yahoo! Finance]
11/1
08:15 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
High
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/31
11:00 am
syrs
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
Low
Report
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
07:30 am
syrs
syros pharmaceuticals, inc.
BEAT
Report
-2.3%
syros pharmaceuticals, inc.
7/31/2024
07:30 am
syrs
syros pharmaceuticals, inc.
BEAT
Report
-1.8%
syros pharmaceuticals, inc.
5/14/2024
07:30 am
syrs
syros pharmaceuticals, inc.
BEAT
Report
10.6%
syros pharmaceuticals, inc.
3/27/2024
07:30 am
syrs
syros pharmaceuticals, inc.
MISS
Report
-8.5%
syros pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
05:01 pm
syrs
Form 4 Syros Pharmaceuticals, For: Nov 19 Filed by: Quirk Gerald E
Low
Report
Form 4 Syros Pharmaceuticals, For: Nov 19 Filed by: Quirk Gerald E
11/20
05:01 pm
syrs
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Stephens Kristin
Low
Report
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Stephens Kristin
11/20
05:00 pm
syrs
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Chee Conley
Low
Report
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Chee Conley
11/20
05:00 pm
syrs
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Roth David
Low
Report
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Roth David
11/20
05:00 pm
syrs
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Haas Jason
Low
Report
Form 4 Syros Pharmaceuticals, For: Nov 18 Filed by: Haas Jason
11/19
05:22 pm
syrs
Form 144 Syros Pharmaceuticals, Filed by: Quirk Gerald E
High
Report
Form 144 Syros Pharmaceuticals, Filed by: Quirk Gerald E
11/18
06:01 pm
syrs
Form 144 Syros Pharmaceuticals, Filed by: Haas Jason
High
Report
Form 144 Syros Pharmaceuticals, Filed by: Haas Jason
11/18
05:43 pm
syrs
Form 144 Syros Pharmaceuticals, Filed by: Roth David
High
Report
Form 144 Syros Pharmaceuticals, Filed by: Roth David
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/18
Form 8-K Syros Pharmaceuticals, For: Dec 17
16.2%
12/18 Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at Cowen Inc. 15.7%
8/1 Q2/2019 6/30/2019 EPS -0.470 ZacksConsensus -0.410 ActVsEst (0.060) - Miss 13.4%
12/20 Syros Announces Appointment of Mark Alles to Its Board of Directors 11.6%
8/6 Syros to Present at 2019 Wedbush PacGrow Healthcare Conference 10.6%
3/6 Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "hold" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock. 9.8%
4/2 Form SC 13G Syros Pharmaceuticals, Filed by: Point72 Asset Management, L.P. 8.9%
6/12 Syros to Present at JMP Securities Life Sciences Conference 7.1%
1/12 Syros Announces Strategic Priorities and Expected Milestones 6.9%
1/14 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 6.3%
12/18 Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at Cowen Inc. 15.7%
8/1 Q2/2019 6/30/2019 EPS -0.470 ZacksConsensus -0.410 ActVsEst (0.060) - Miss 13.4%
12/20 Syros Announces Appointment of Mark Alles to Its Board of Directors 11.6%
8/6 Syros to Present at 2019 Wedbush PacGrow Healthcare Conference 10.6%
3/6 Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "hold" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock. 9.8%
4/2 Form SC 13G Syros Pharmaceuticals, Filed by: Point72 Asset Management, L.P. 8.9%
6/12 Syros to Present at JMP Securities Life Sciences Conference 7.1%
1/12 Syros Announces Strategic Priorities and Expected Milestones 6.9%
1/14 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 6.3%
TOP News Decliners
10/17
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
-34.3%
10/24 Form 8-K Syros Pharmaceuticals, For: Oct 24 -15.2%
7/14 Syros Pharmaceuticals Inc (NASDAQ: SYRS) is now covered by analysts at Roth Capital. They set a "buy" rating and a $17.00 price target on the stock. -14.1%
3/6 Form 424B5 Syros Pharmaceuticals, -12.2%
2/24 Syros to Present at Upcoming Investor Conferences in March -9.0%
6/11 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.4%
5/7 New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers -6.4%
10/18 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -6.3%
12/2 Form 8-K Syros Pharmaceuticals, For: Dec 02 -5.7%
10/8 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -5.5%
10/24 Form 8-K Syros Pharmaceuticals, For: Oct 24 -15.2%
7/14 Syros Pharmaceuticals Inc (NASDAQ: SYRS) is now covered by analysts at Roth Capital. They set a "buy" rating and a $17.00 price target on the stock. -14.1%
3/6 Form 424B5 Syros Pharmaceuticals, -12.2%
2/24 Syros to Present at Upcoming Investor Conferences in March -9.0%
6/11 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.4%
5/7 New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers -6.4%
10/18 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -6.3%
12/2 Form 8-K Syros Pharmaceuticals, For: Dec 02 -5.7%
10/8 Syros Pharmaceuticals Inc (NASDAQ: SYRS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -5.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: